ATE368103T1 - Isolierung, vermehrung und gezielte differenzierung von zäugetierstammzellen des zentralnervensystems - Google Patents

Isolierung, vermehrung und gezielte differenzierung von zäugetierstammzellen des zentralnervensystems

Info

Publication number
ATE368103T1
ATE368103T1 AT97923569T AT97923569T ATE368103T1 AT E368103 T1 ATE368103 T1 AT E368103T1 AT 97923569 T AT97923569 T AT 97923569T AT 97923569 T AT97923569 T AT 97923569T AT E368103 T1 ATE368103 T1 AT E368103T1
Authority
AT
Austria
Prior art keywords
stem cells
propagation
isolation
free
nervous system
Prior art date
Application number
AT97923569T
Other languages
English (en)
Inventor
Karl Johe
Original Assignee
Neuralstem Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26690851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE368103(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralstem Biopharmaceuticals filed Critical Neuralstem Biopharmaceuticals
Application granted granted Critical
Publication of ATE368103T1 publication Critical patent/ATE368103T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97923569T 1996-05-23 1997-05-07 Isolierung, vermehrung und gezielte differenzierung von zäugetierstammzellen des zentralnervensystems ATE368103T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1820696P 1996-05-23 1996-05-23
US08/719,450 US5753506A (en) 1996-05-23 1996-09-25 Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals

Publications (1)

Publication Number Publication Date
ATE368103T1 true ATE368103T1 (de) 2007-08-15

Family

ID=26690851

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97923569T ATE368103T1 (de) 1996-05-23 1997-05-07 Isolierung, vermehrung und gezielte differenzierung von zäugetierstammzellen des zentralnervensystems

Country Status (8)

Country Link
US (2) US5753506A (de)
EP (1) EP0915968B2 (de)
AT (1) ATE368103T1 (de)
AU (1) AU2934197A (de)
CA (1) CA2257068C (de)
DE (1) DE69737949T3 (de)
ES (1) ES2292187T5 (de)
WO (1) WO1997044442A1 (de)

Families Citing this family (283)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037721B1 (en) * 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US7361505B1 (en) 1991-07-08 2008-04-22 Neurospheres Holdings Ltd. Multipotent neural stem cell compositions
US6399369B1 (en) 1991-07-08 2002-06-04 Neurospheres Holdings Ltd. Multipotent neural stem cell cDNA libraries
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US7166277B1 (en) 1991-07-08 2007-01-23 Neurospheres Holdings Ltd. Remyelination of neurons using multipotent neural stem cell progeny
US5910161A (en) * 1994-09-20 1999-06-08 Fujita; Makoto Refrigerating apparatus
US7544511B2 (en) 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US6787355B1 (en) * 1996-08-26 2004-09-07 Mcgill University Multipotent neural stem cells from peripheral tissues and uses thereof
US6969608B1 (en) 1996-08-26 2005-11-29 Mcgill University Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
WO1998030678A1 (en) * 1997-01-07 1998-07-16 Steindler Dennis A Isolated mammalian neural stem cells, methods of making such cells, and methods of using such cells
US6245564B1 (en) 1997-01-23 2001-06-12 Cornell Research Foundation, Inc. Method for separating cells
US6361996B1 (en) * 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
AU7963998A (en) 1997-06-13 1998-12-30 University Technology Corporation Transplantation of immortalized dopamine cells to improve neurological deficits
US6235527B1 (en) * 1997-11-29 2001-05-22 University Of Utah Research Foundation Lineage restricted glial precursors from the central nervous system
US6734015B1 (en) * 1997-07-04 2004-05-11 University Of Utah Research Foundation Isolation of lineage-restricted neuronal precursors
US20020016002A1 (en) * 2000-01-24 2002-02-07 Jean Toma Multipotent neural stem cells from peripheral tissues and uses thereof
US20020123143A1 (en) * 1997-08-22 2002-09-05 Jean Toma Multipotent stem cells from peripheral tissues and uses thereof
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6126955A (en) * 1998-04-16 2000-10-03 University Of Utah Research Foundation Apo-transferrin as a potent inhibitor of bacterial adhesion to biomaterials
US6027744A (en) * 1998-04-24 2000-02-22 University Of Massachusetts Medical Center Guided development and support of hydrogel-cell compositions
US6171610B1 (en) * 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
AU3888699A (en) 1998-05-07 1999-11-23 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
US20080206206A1 (en) 1998-05-07 2008-08-28 University Of South Florida Bone marrow-derived neuronal cells
SE9802264D0 (sv) * 1998-06-25 1998-06-25 Neuronova Ab A method of isolating cells
US6541247B1 (en) * 1998-06-25 2003-04-01 Neuronova Ab Method of isolating ependymal neural stem cells
JP2002521025A (ja) * 1998-07-24 2002-07-16 ザ カーネギー インスチチューション オブ ワシントン 増殖因子のＴＧＦ−βファミリーのメンバーを使用する、生殖系列幹細胞の維持および増殖のための方法。
US20020115213A1 (en) * 1998-08-14 2002-08-22 Northeastern Ohio Universities Of Medicine Engraftable neural progenitor & stem cells for brain tumor therapy
US7186409B2 (en) * 1998-08-14 2007-03-06 The Children's Medical Center Corporation Neural stem cells and use thereof for brain tumor therapy
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
AU755849B2 (en) * 1998-09-22 2002-12-19 Neuralstem Biopharmaceuticals, Ltd. Stable neural stem cell lines
EP1036162B1 (de) * 1998-10-07 2013-03-06 The Children's Medical Center Corporation Transplantierbare neuronale stammzellen zur therapie von gehirntumoren
US8263402B1 (en) 1998-10-19 2012-09-11 Cornell Research Foundation, Inc. Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US20020168766A1 (en) * 2000-01-11 2002-11-14 Gold Joseph D. Genetically altered human pluripotent stem cells
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
SE9900134D0 (sv) * 1999-01-15 1999-01-15 A & Science Invest Ab A method for introducing substances into cells, and use of said method
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
US7041507B1 (en) 1999-01-20 2006-05-09 Cedars-Sinai Medical Center Transdiffentiation of transfected epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
WO2000047718A1 (en) * 1999-02-11 2000-08-17 The Salk Institute For Biological Studies Isolation of stem cells and methods of use thereof
US7105150B2 (en) * 1999-02-12 2006-09-12 Stemcells California, Inc. In vivo screening methods using enriched neural stem cells
US7037719B1 (en) 1999-02-12 2006-05-02 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
ES2351170T3 (es) 1999-02-12 2011-02-01 Stemcells California, Inc. Poblaciones enriquecidas de células del sistema nervioso central.
US7217565B2 (en) * 1999-02-12 2007-05-15 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US6468794B1 (en) 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US6238922B1 (en) 1999-02-26 2001-05-29 Stemcells, Inc. Use of collagenase in the preparation of neural stem cell cultures
GB9907243D0 (en) * 1999-03-29 1999-05-26 Reneuron Ltd Therapy
EP1179046B1 (de) * 1999-05-07 2006-03-08 University Of Utah Research Foundation Auf eine zellinie beschränkte vorläuferzellen aus dem neuralrohr der maus und aus embryonalen stammzellen der maus
US6852685B1 (en) * 1999-08-17 2005-02-08 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof to promote neuronal cell differentiation
US7119064B2 (en) * 1999-08-17 2006-10-10 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules
US6500798B1 (en) * 1999-08-17 2002-12-31 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators
US6903068B1 (en) 1999-08-17 2005-06-07 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US20050118143A1 (en) * 1999-10-01 2005-06-02 Steindler Dennis A. Isolated mammalian neural stem cells, methods of making such cells, and methods of using such cells
ES2208024B1 (es) * 1999-10-14 2005-10-01 Universidad Miguel Hernandez Un metodo para obtener in vitro celulas madre de individuos mamiferos adultos.
US6878543B1 (en) * 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
WO2001042421A2 (en) * 1999-12-07 2001-06-14 Monash University Long-term cell culture compositions and genetically modified animals derived therefrom
AUPQ463799A0 (en) * 1999-12-14 2000-01-13 Novio Phenolic Foam Pty Ltd Fire resistant compositions
US7468277B2 (en) * 1999-12-23 2008-12-23 Cornell Research Foundation, Inc. Enriched preparation of human fetal multipotential neural stem cells
US7560275B2 (en) * 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
US7575921B2 (en) * 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US20050042749A1 (en) * 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
US7455983B2 (en) * 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
US7785882B2 (en) * 2000-01-18 2010-08-31 Cornell Research Foundation, Inc. Neuronal progenitor cells from hippocampal tissue and a method for isolating and purifying them
US6395546B1 (en) * 2000-02-01 2002-05-28 Neurogeneration, Inc. Generation of dopaminergic neurons from human nervous system stem cells
AU3499801A (en) * 2000-02-11 2001-08-20 Schepens Eye Res Inst Isolation and transplantation of retinal stem cells
JP4800544B2 (ja) * 2000-03-15 2011-10-26 チルドレンズ メディカル センター コーポレーション 腫瘍治療用の全身性遺伝子送達運搬体
US6673606B1 (en) 2000-04-12 2004-01-06 The Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
US7037493B2 (en) 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US6828145B2 (en) 2000-05-10 2004-12-07 Cedars-Sinai Medical Center Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker
US8273570B2 (en) * 2000-05-16 2012-09-25 Riken Process of inducing differentiation of embryonic cell to cell expressing neural surface marker using OP9 or PA6 cells
WO2001088100A1 (en) * 2000-05-16 2001-11-22 Kyowa Hakko Kogyo Co., Ltd. Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof
US7250294B2 (en) * 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
WO2001088104A2 (en) * 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations
EP1353549A2 (de) * 2000-06-01 2003-10-22 PHARMACIA & UPJOHN COMPANY Wfs1 heterozygote mäuse als depressionsmuster
US6897061B1 (en) * 2000-06-16 2005-05-24 Spinal Cord Society Transdifferentiation of glial cells
US7010351B2 (en) * 2000-07-13 2006-03-07 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7672730B2 (en) * 2001-03-08 2010-03-02 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US20030125786A1 (en) * 2000-07-13 2003-07-03 Gliner Bradford Evan Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7831305B2 (en) * 2001-10-15 2010-11-09 Advanced Neuromodulation Systems, Inc. Neural stimulation system and method responsive to collateral neural activity
US7024247B2 (en) 2001-10-15 2006-04-04 Northstar Neuroscience, Inc. Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures
US7756584B2 (en) * 2000-07-13 2010-07-13 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7305268B2 (en) 2000-07-13 2007-12-04 Northstar Neurscience, Inc. Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators
US7236831B2 (en) 2000-07-13 2007-06-26 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7146217B2 (en) * 2000-07-13 2006-12-05 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a change in a neural-function of a patient
JP4031901B2 (ja) * 2000-07-19 2008-01-09 株式会社東芝 固体撮像装置
JP2004504834A (ja) * 2000-08-01 2004-02-19 イスム　リサーチ　ディベロップメント　カンパニー 胚性細胞の定方向分化
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) * 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
AUPR095200A0 (en) * 2000-10-24 2000-11-16 Bresagen Limited Cell production
US20020151050A1 (en) * 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
WO2002063938A2 (en) * 2000-12-05 2002-08-22 Layton Bioscience Inc. Production and use of dopaminergic cells to treat dopaminergic deficiencies
EP1366148A2 (de) * 2001-01-24 2003-12-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Differenzierung von stammzellen zu endokrinen pankreaszellen
WO2002072762A2 (en) * 2001-03-08 2002-09-19 Advanced Cell Technology, Inc. Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
US7299096B2 (en) * 2001-03-08 2007-11-20 Northstar Neuroscience, Inc. System and method for treating Parkinson's Disease and other movement disorders
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US6506576B2 (en) 2001-03-14 2003-01-14 Board Of Trustees Of The University Of Arkansas Serum-and steroid-free culture media for cerebellar granule neurons
US7838292B1 (en) * 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
WO2002083877A1 (en) * 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
KR100449141B1 (ko) * 2001-04-19 2004-09-21 (주)라이프코드 간엽 간세포를 신경세포로 분화시키는 방법
WO2002086073A2 (en) * 2001-04-20 2002-10-31 Memorial Sloan-Kettering Cancer Center Generation of differentiated tissue from nuclear transfer embryonic stem cells and methods of use
EP1385938A1 (de) * 2001-04-23 2004-02-04 Nsgene A/S Methode und kulturmedium zur herstellung von neuronalenzellen ausdrücken tyrosin hydroxylase
US20020179544A1 (en) * 2001-04-27 2002-12-05 Nexell Therapeutics, Inc. Cell processing and fluid transfer apparatus and method of use
AU2007251905B2 (en) * 2001-04-27 2012-04-26 Stem Cell Therapeutics Inc. Neural progenitor cells
US7943376B2 (en) * 2001-04-27 2011-05-17 Stem Cell Therapuetics Inc. Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
EP1397485A2 (de) * 2001-06-05 2004-03-17 Thomas Rohrmeier Zellpopulationen zur auffindung neuronaler targets und potentieller wirkstoffe
WO2002102988A2 (en) * 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
AU2002315337A1 (en) * 2001-06-18 2003-01-02 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using valproate
CA2364095C (en) * 2001-07-20 2011-07-12 Neurostasis, Inc Production of radial glial cells
EP1423504B1 (de) * 2001-08-08 2009-09-23 Levesque Biosciences, Inc. Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen
AU2002327433A1 (en) 2001-08-10 2003-02-24 Cornell Research Foundation, Inc. Telomerase immortalized human neutral stem cells and phenotypically-restricted progenitor cells
US20040092013A1 (en) * 2001-08-14 2004-05-13 Snyder Evan Y. Method of treating alzheimer's disease with cell therapy
AR036400A1 (es) * 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de) * 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
WO2003026738A1 (en) * 2001-09-28 2003-04-03 Northstar Neuroscience, Inc. Methods and apparatus for electrically stimulating cells implanted in the nervous system
US20030119080A1 (en) * 2001-10-15 2003-06-26 Mangano Joseph A. Strategies for the identification and isolation of cancer stem cells and non-cancerous stem cells
US7129034B2 (en) * 2001-10-25 2006-10-31 Cedars-Sinai Medical Center Differentiation of whole bone marrow
AU2002364537A1 (en) * 2001-12-07 2003-06-23 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
AU2003202988A1 (en) * 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
EP1472340A4 (de) * 2002-02-05 2006-11-08 Rappaport Family Inst For Res Für telomerasepromotoraktivität ausgewählte, zellinienmässig festgelegte stammzellen
WO2003068357A2 (en) * 2002-02-12 2003-08-21 Cornell Research Foundation, Inc. Identification and high-yield isolation of human pancreatic islet progenitor and stem cells
AU2003215297A1 (en) * 2002-02-15 2003-09-09 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US7221981B2 (en) * 2002-03-28 2007-05-22 Northstar Neuroscience, Inc. Electrode geometries for efficient neural stimulation
US20050101014A1 (en) * 2002-07-11 2005-05-12 Keirstead Hans S. Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
US7285415B2 (en) 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
AU2003249227A1 (en) * 2002-07-12 2004-02-02 University Of Washington Methods and systems for extended in vitro culture of neuronal cells
US7390659B2 (en) * 2002-07-16 2008-06-24 The Trustees Of Columbia University In The City Of New York Methods for inducing differentiation of embryonic stem cells and uses thereof
US20040224302A1 (en) * 2002-07-16 2004-11-11 Thomas Jessel Systems and methods for screening for modulators of neural differentiation
US7632679B2 (en) * 2002-07-16 2009-12-15 The Trustees Of Columbia University In The City Of New York Systems and methods for screening for modulators of neural differentiation
CA2492442A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
WO2004015077A2 (en) * 2002-08-08 2004-02-19 University Of Georgia Research Foundation, Inc. Compositions and methods for neural differentiation of embryonic stem cells
AU2003278741B2 (en) * 2002-08-27 2008-02-14 Stemcells California Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US20040043009A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of repairing primate mammalian tissue
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040076620A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of repairing primate mammalian tissue
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040042997A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of regenerating human tissue
US20040076605A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of regenerating human tissue
KR100495532B1 (ko) * 2002-09-18 2005-06-14 에프씨비파미셀 주식회사 간엽 간세포를 신경세포로 분화 및 증식시키는 방법
WO2004029203A2 (en) * 2002-09-25 2004-04-08 Bresagen, Inc. Compositions and methods for enrichment of neural stem cells using ceramide analogs
US20050075679A1 (en) * 2002-09-30 2005-04-07 Gliner Bradford E. Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system
AU2003301559A1 (en) * 2002-10-22 2004-05-13 Board Of Regents The University Of Texas System Colostrinin and peptides thereof as modulators of intracellular signaling molecules and inhibitors of apoptosis
US20040147020A1 (en) * 2002-11-01 2004-07-29 The Regents Of The University Of Colorado, A Body Corporate Dopamine neurons from human embryonic stem cells
US7236830B2 (en) * 2002-12-10 2007-06-26 Northstar Neuroscience, Inc. Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders
US20050075680A1 (en) * 2003-04-18 2005-04-07 Lowry David Warren Methods and systems for intracranial neurostimulation and/or sensing
US7302298B2 (en) * 2002-11-27 2007-11-27 Northstar Neuroscience, Inc Methods and systems employing intracranial electrodes for neurostimulation and/or electroencephalography
US20040185429A1 (en) 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
AU2003297761A1 (en) * 2002-12-09 2004-06-30 Northstar Neuroscience, Inc. Methods for treating neurological language disorders
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
US6959215B2 (en) * 2002-12-09 2005-10-25 Northstar Neuroscience, Inc. Methods for treating essential tremor
US20060211111A1 (en) * 2002-12-18 2006-09-21 Maisam Mitalipova Compositions and methods for neural cell production and stabilization
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
CA2548580A1 (en) * 2003-04-03 2004-10-21 Neostem, Inc. Elective collection and banking of autologous peripheral blood stem cells
CA2522712A1 (en) * 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. Nerve regenerating drug
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
IL155783A (en) 2003-05-05 2010-11-30 Technion Res & Dev Foundation Multicellular systems of pluripotent human embryonic stem cells and cancer cells and uses thereof
EP1624936B1 (de) 2003-05-16 2009-10-28 Universite Laval Cns chlorid-modulierung und verwendung derselben
EP1629089A1 (de) * 2003-06-03 2006-03-01 Organ Recovery Systems, Inc. Selektion und vermehrung von vorläuferzellen
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AR046076A1 (es) * 2003-07-18 2005-11-23 Otsuka Pharma Co Ltd Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
EP1654032A2 (de) * 2003-08-01 2006-05-10 Northstar Neuroscience, Inc. Gerät und verfahren für die neurale stimulation eines patienten
WO2005017189A2 (en) * 2003-08-05 2005-02-24 University Of Florida Research Foundation, Inc. Neural cell assay
WO2005033297A1 (en) * 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
US20070269412A1 (en) * 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
JP4676442B2 (ja) * 2003-12-02 2011-04-27 セラヴィー バイオサイエンシズ エルエルシー 神経前駆細胞を増殖させるための組成物および方法
CA2560544C (en) 2004-01-16 2015-05-19 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US7829332B2 (en) * 2004-02-13 2010-11-09 Cornell Research Foundation, Inc. Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
WO2005089420A2 (en) * 2004-03-16 2005-09-29 Theradigm, Inc. Expansion of neural stem cells with lif
NL1026137C2 (nl) * 2004-05-07 2005-11-08 Vanderlande Ind Nederland Inrichting voor het sorteren van producten.
NZ551832A (en) * 2004-06-09 2010-01-29 Univ Edinburgh Neural stem cells
KR100563297B1 (ko) * 2004-06-16 2006-03-27 시 명 김 골프공 이송장치
US7456019B2 (en) 2004-06-30 2008-11-25 Regenetech, Inc. Three-dimensional cell to tissue development process
US20060228795A1 (en) * 2004-06-30 2006-10-12 Parker Clayton R Apparatus for enhancing proliferation of cells in a small-scale cell culturing container
US20080044890A1 (en) * 2004-06-30 2008-02-21 Parker Clayton R Interchangable sleeve for enhancing proliferation of cells in a rotating bioreactor
JP2008506464A (ja) 2004-07-15 2008-03-06 ノーススター ニューロサイエンス インコーポレイテッド 神経刺激効率及び／又は効力の強化又はそれに影響を及ぼすためのシステム及び方法
AU2005286097A1 (en) * 2004-09-21 2006-03-30 Nvr Labs. Ltd. Compositions and methods for stem cell expansion and differentiation
US7565200B2 (en) * 2004-11-12 2009-07-21 Advanced Neuromodulation Systems, Inc. Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects
US20060106430A1 (en) * 2004-11-12 2006-05-18 Brad Fowler Electrode configurations for reducing invasiveness and/or enhancing neural stimulation efficacy, and associated methods
EP1814979B1 (de) 2004-11-17 2015-04-08 Neuralstem, Inc. Transplantation menschlicher nervenzellen zur behandlung neurodegenerativer erkrankungen
WO2006056998A2 (en) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Methods of cell therapy, neurogenesis and oligodendrogenesis
US7629169B2 (en) * 2004-12-01 2009-12-08 Stem Cell Therapeutics Corp. Methods for the production of platelet-derived growth factor-responsive neural precursor cells
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2006116717A2 (en) * 2005-04-28 2006-11-02 The Board Of Regents Of The University Of Texas System Autologous somatic cells from peripheral blood and uses thereof
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP2317316A3 (de) 2005-07-08 2011-06-15 Braincells, Inc. Verfahren zur Identifizierung von neurogenesemodulierenden Wirkstoffen und Bedingungen
US20070054397A1 (en) * 2005-08-26 2007-03-08 Harald Ott Adult cardiac uncommitted progenitor cells
WO2008020815A1 (en) 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
WO2007036033A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
US8929991B2 (en) 2005-10-19 2015-01-06 Advanced Neuromodulation Systems, Inc. Methods for establishing parameters for neural stimulation, including via performance of working memory tasks, and associated kits
US20070088403A1 (en) * 2005-10-19 2007-04-19 Allen Wyler Methods and systems for establishing parameters for neural stimulation
US7729773B2 (en) 2005-10-19 2010-06-01 Advanced Neuromodualation Systems, Inc. Neural stimulation and optical monitoring systems and methods
CA2628255C (en) * 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
WO2007106987A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
WO2007120911A2 (en) * 2006-04-14 2007-10-25 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
WO2008054509A2 (en) * 2006-04-14 2008-05-08 Celsense, Inc. Methods for assessing cell labeling
US20080038231A1 (en) 2006-06-15 2008-02-14 Rodgerson Denis O Processing procedure for peripheral blood stem cells
US20080003676A1 (en) * 2006-06-26 2008-01-03 Millipore Corporation Growth of embryonic stem cells
US20100068187A1 (en) * 2006-08-31 2010-03-18 Roisen Fred J Transcription factors for differentiation of adult human olfactory progenitor cells
WO2008092002A2 (en) * 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US20080249591A1 (en) * 2007-04-06 2008-10-09 Northstar Neuroscience, Inc. Controllers for implantable medical devices, and associated methods
WO2008127974A1 (en) * 2007-04-13 2008-10-23 The Trustees Of Columbia University In The City Of New York Stem cell-based culture system for drug development
WO2008134406A1 (en) * 2007-04-25 2008-11-06 The Board Of Trustees Of The Leland Stanford Junior University Ischemia-induced neovascularization is enhanced by hcns-sc transplantation
EP2607477B1 (de) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotente stammzellen und ihre verwendung
US8574567B2 (en) * 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
CA2689484A1 (en) * 2007-06-06 2008-12-11 The Hospital For Sick Children Skin-derived precursor cells and uses thereof
CA2693678C (en) * 2007-07-10 2017-02-14 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
US20090136461A1 (en) * 2007-11-28 2009-05-28 Moon Suk Kim Neuronal differentiation method of adult stem cells using small molecules
SG188096A1 (en) 2008-01-30 2013-03-28 Geron Corp Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
JP2011514169A (ja) 2008-03-17 2011-05-06 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 幹細胞培養のためのマイクロキャリア
US20100040583A1 (en) * 2008-03-27 2010-02-18 Vincent Falanga Compositions and methods using stem cells in cutaneous wound healing
US20110110863A1 (en) * 2008-05-02 2011-05-12 Celsense, Inc. Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
US20120052003A9 (en) * 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US8669048B2 (en) * 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US8748177B2 (en) 2008-09-30 2014-06-10 The Hospital For Sick Children Compositions for proliferation of cells and related methods
US8969081B2 (en) * 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
EP3187581A1 (de) 2008-12-23 2017-07-05 BOCO Silicon Valley, Inc. Zielpopulationen von oligodendrozyten-vorläuferzellen und verfahren zur herstellung und verwendung davon
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
WO2011011477A1 (en) 2009-07-21 2011-01-27 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
WO2011011500A1 (en) 2009-07-21 2011-01-27 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
EP2499240A1 (de) 2009-11-12 2012-09-19 Vbi Technologies, LLC Subpopulationen von sporenartigen zellen und verwendungen davon
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
DK2539436T3 (da) 2010-02-25 2021-10-18 Abt Holding Co Modulering af makrofagaktivering
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
NZ623207A (en) 2010-07-28 2014-12-24 Neuralstem Inc Methods for treating and/or reversing neurodegenerative diseases and/or disorders
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP6126004B2 (ja) 2010-10-25 2017-05-10 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 血小板の生成のための組成物および方法、およびそれらの使用の方法
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2012151266A1 (en) 2011-05-03 2012-11-08 Michael Har-Noy Methods for handling biological drugs containing living cells
PL2718416T3 (pl) 2011-06-06 2020-05-18 ReGenesys BVBA Namnażanie komórek macierzystych w bioreaktorach włóknisto-kapilarnych
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
ES2700980T3 (es) 2012-02-17 2019-02-20 Schepens Eye Res Inst Perfil fenotípico de células progenitoras de retina humana
GB201302468D0 (en) 2013-02-12 2013-03-27 Reneuron Ltd Stem cell product
EP2833893B1 (de) 2012-04-03 2018-08-29 Reneuron Limited Stammzellenmikropartikel
SG11201500329WA (en) 2012-07-19 2015-02-27 Reneuron Ltd Stem cell microparticles
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US20160002597A1 (en) 2013-02-12 2016-01-07 Reneuron Limited Method of producing microparticles
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP2970877B1 (de) 2013-03-15 2018-07-25 Wake Forest University Health Sciences Differenzierung neuronaler vorläuferzellen
IL289870B2 (en) 2013-04-12 2023-03-01 Lafrancesca Saverio Improving organs for transplantation
AU2014266935B2 (en) 2013-04-30 2020-06-11 Katholieke Universiteit Leuven Cell therapy for myelodysplastic syndromes
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
GB201317889D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product and use
US8916339B1 (en) 2013-10-31 2014-12-23 Vivex Biomedical, Inc. Spinal cord tissue dehydrated and micronized
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
WO2016064737A1 (en) 2014-10-20 2016-04-28 Neuralstem, Inc. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
US9402869B1 (en) 2015-03-27 2016-08-02 Vivex Biomedical, Inc. Treated neural tissue composition
EP3283529B1 (de) 2015-04-17 2023-06-07 The General Hospital Corporation Wirkstoffe, systeme und verfahren zur behandlung von krebs
EP3288570A4 (de) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modifizierte stammzellen und verwendungen davon
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017147212A1 (en) 2016-02-22 2017-08-31 The Regents Of The University Of California Compositions and methods for imaging cell populations
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
WO2019241499A1 (en) 2018-06-13 2019-12-19 Miromatrix Medical Inc. Fistula filler and deployment system
WO2020076614A1 (en) 2018-10-08 2020-04-16 Allen Institute Artificial expression constructs for selectively modulating gene expression in interneurons
WO2021007180A1 (en) 2019-07-05 2021-01-14 Case Western Reserve University Priming media and methods for stem cell culture and therapy
GB201919021D0 (en) 2019-12-20 2020-02-05 Reneuron Ltd Nucleic acid constructs for delivering polynucleotides into exosomes
CN112226411A (zh) * 2020-10-16 2021-01-15 武汉睿健医药科技有限公司 一种化学培养体系及其应用
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
GB202114441D0 (en) 2021-10-08 2021-11-24 Reneuron Ltd Proteins and extracellular vesicles
CN113881634A (zh) * 2021-10-18 2022-01-04 中山大学中山眼科中心 一种原代成年灵长类动物海马神经干细胞团的培养方法
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN118895246A (zh) * 2024-08-09 2024-11-05 广东龄值生物科技有限公司 一种神经干细胞的分离与体外培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226750A (en) * 1987-10-29 1990-09-26 Amrad Corp Ltd Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5589376A (en) * 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
NZ256154A (en) * 1992-07-27 1997-02-24 California Inst Of Techn Production of mammalian multipotent neural stem cells, antibodies
KR950704476A (ko) * 1992-10-28 1995-11-20 브렌드 레이놀즈 생물학적 인자 및 신경 간세포(biological factors and neural stem cells)
ES2167461T3 (es) * 1994-09-23 2002-05-16 Neurospheres Holdings Ltd Modelos in vitro de funcion y disfuncion del sistema nervioso central.

Also Published As

Publication number Publication date
US5753506A (en) 1998-05-19
DE69737949D1 (de) 2007-09-06
DE69737949T3 (de) 2015-01-08
WO1997044442A1 (en) 1997-11-27
ES2292187T3 (es) 2008-03-01
DE69737949T2 (de) 2008-04-10
ES2292187T5 (es) 2015-02-10
CA2257068C (en) 2013-04-30
EP0915968B2 (de) 2014-10-22
AU2934197A (en) 1997-12-09
EP0915968B1 (de) 2007-07-25
CA2257068A1 (en) 1997-11-27
US6040180A (en) 2000-03-21
EP0915968A1 (de) 1999-05-19

Similar Documents

Publication Publication Date Title
ATE368103T1 (de) Isolierung, vermehrung und gezielte differenzierung von zäugetierstammzellen des zentralnervensystems
Bonney et al. Primary monolayer cultures of adult rat liver parenchymal cells suitable for study of the regulation of enzyme synthesis
ATE288481T1 (de) Verwendung von collagenase in der zubereitung von neuralen stammzellkulturen
Simpson et al. Prevention of hybridoma cell death by bcl‐2 during suboptimal culture conditions
CA2402299A1 (en) Serum free cultivation of primate embryonic stem cells
SI1543106T1 (sl) Postopki in mediji za nadziranje sialilacije proteinov, ki jih proizvajajo sesalske celice
NO20022180D0 (no) Hematopoietisk differensiering av humane embryoniske stamceller
DK1576182T4 (da) Produktkvalitetsforbedring ved fremgangsmåde med dyrkning af pattedyreceller til proteinfremstilling
EA199800835A1 (ru) Среда для культуры клеток млекопитающихся, способ ее получения и смесь компонентов, композиция, способы получения, продуцирования клонального роста, размножения и изменения фенотипа гепатоцитов in vitro, клетки, фармацевтический состав, способы получения рекомбинантной клетки и генного продукта, способы использования клеток, способ трансплантации гепатоцитов, способ испытания лекарственного препарата, способ поддержания жизнеспособности дифференцированных гепатоцитов
ES2090297T3 (es) Produccion de proteinas que utilizan recombinacion homologa.
DK1084230T3 (da) Regulering af hæmatopoietisk stamcelledifferentiering ved anvendelse af humane mesenkymstamceller
PT889949E (pt) Controlo de fermentacao
EP1007630A4 (de) Natürliche killerzelllinien und verfahren zu ihrer verwendung
ATE200625T1 (de) Leberreservezellen
IL94611A0 (en) Cell culture systems and media
EP0453453A4 (en) Leukaemia inhibitory factor from livestock species and use thereof to enhance implantation and development of embryonic cells
WO2004090096A3 (en) Methods for neural differentiation of embryonic stem cells using protease passaging techniques
IL155482A (en) Method for increasing product yield of a mammalian polypeptide produced by recombinant bacterial host cells
DK0587873T3 (da) Fremgangsmåde til opnåelse af celler, der er inficeret med en virus, der er forbundet med dissemineret sklerose
Tang et al. Rapid Communication: Differentiation of Embryonic Stem Cell to Astrocytes Visualized by Green Fluorescent Protein
EP0927043B8 (de) Zusammensetzungen zur gentransfer in das zentrale nervensystem
Chiang et al. Successful induction of antisera against rabbit embryos for isolation of the ICM and putative embryonic stem cells
DK1238057T3 (da) Fremgangsmåde til produktion af vedhæftende dyreceller
Blüthmann et al. Enzyme activity profiles in mouse teratocarcinomas: a quantitative ultramicroscale analysis
GB9828624D0 (en) Production of proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties